| Autor: |
Bednarska, Karolina, Chowdhury, Rakin, Tobin, Joshua W. D., Swain, Fiona, Keane, Colm, Boyle, Stephen, Khanna, Rajiv, Gandhi, Maher K. |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; Feb2024, Vol. 204 Issue 2, p415-433, 19p |
| Abstrakt: |
Summary: Epstein–Barr virus (EBV)‐associated lymphomas cover a range of histological B‐ and T‐cell non‐Hodgkin and Hodgkin lymphoma subtypes. The role of EBV on B‐cell malignant pathogenesis and its impact on the tumour microenvironment are intriguing but incompletely understood. Both the International Consensus Classification (ICC) and 5th Edition of the World Health Organization (WHO‐HAEM5) proposals give prominence to the distinct clinical, prognostic, genetic and tumour microenvironmental features of EBV in lymphoproliferative disorders. There have been major advances in our biological understanding, in how to harness features of EBV and its host immune response for targeted therapy, and in using EBV as a method to monitor disease response. In this article, we showcase the latest developments and how they may be integrated to stimulate new and innovative approaches for further lines of investigation and therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text